Idelalisib-associated enterocolitis

American Journal of Surgical Pathology

Volumn 39, Issue 12, 2015, Pages 1653-1660

  Louie, Christine Y ^a   Dimaio, Michael A ^a   Matsukuma, Karen E ^b   Coutre, Steven E ^a   Berry, Gerald J ^a   Longacre, Teri A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apoptosis; CLL; enterocolitis; gastrointestinal; idelalisib

Indexed keywords

ANTINEOPLASTIC AGENT; IDELALISIB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

AGED; ANTAGONISTS AND INHIBITORS; BIOPSY; CHEMICALLY INDUCED; CHEMISTRY; COLONOSCOPY; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; ENTEROCOLITIS; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; ENTEROCOLITIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PURINES; QUINAZOLINONES;

EID: 84948718203     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000525     Document Type: Article

References (21)

1. Lannutti BJ, Meadows SA, Herman SEM, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117: 591-594
2. Herman SEM, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-d inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116: 2078-2088
3. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123: 3390-3397
4. Gopal AK, Kahl BS, de Vos S, et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014; 370: 1008-1018
5. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997-1007
6. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014; 123: 3406-3413
7. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014; 123: 3398-3405
8. Coutre SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment-expert panel opinion. Leuk Lymphoma. 2015: 1-20
9. Weidner A-S, Panarelli N, Geyer J, et al. Idelalisib is a novel biologic agent that can cause severe gastrointestinal toxicity (United States and Canadian Acadamy of Pathology Meeting, Abstract 786). Mod Pathol . 2015; 28: 198A
10. Hendy P, Rosty C, Bashford A, et al. Idelalisib-induced acute proctocolitis: clinical and histological findings. Abstract P223. J Crohns Colitis. 2015; 9(suppl 1): S186-S187
11. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetilrelated gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol. 2008; 32: 1367-1372
12. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010; 126: e243-e246
13. Goetz M, Atreya R, Ghalibafian M, et al. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007; 13: 1365-1368
14. El Fassi D, Nielsen CH, Kjeldsen J, et al. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut. 2008; 57: 714-715
15. Uno JK, Rao KN, Matsuoka K, et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110d. Gastroenterology. 2010; 139: 1642-1653. 1653.e1-6
16. Wei B, Velazquez P, Turovskaya O, et al. Mesenteric B cells centrally inhibit CD4+T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci USA. 2005; 102: 2010-2015
17. Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-Associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008; 32: 1130-1137
18. Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol Baltim Md 1950. 2006; 177: 4376-4383
19. Reuben JM, Lee B-N, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006; 106: 2437-2444
20. Fecker LF, Stockfleth E, Nindl I, et al. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007; 156(suppl 3): 25-33
21. Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci CMLS. 2008; 65: 1295-1301.